Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 25 - Novel Psychoactive Substances: A New Challenge for Prevention and Treatment

  • from Part V - Ongoing and Future Research Directions
  • Edited by Steve Sussman, University of Southern California
  • Book:
    The Cambridge Handbook of Substance and Behavioral Addictions
    Published online:
    13 July 2020
    Print publication:
    06 August 2020, pp 307-325

  • Summary

    In the past two decades, the emergence of Novel Psychoactive Substances (NPS) has changed the face of drug markets. Synthetic cathinones, synthetic cannabinoid receptor agonists, novel synthetic opioids, tryptamines, and piperazines became popular alternatives to illicit drugs, primarily because of their easy availability, low price, and intense effects. Analogous NPS are also often misold as traditional drugs due to the often broader profit margins and lower criminal risk profile associated with them. This chapter aims to provide an overview of the epidemiology, user and consumption characteristics, toxicity, and pharmacokinetics of the most proliferate NPS, alongside an introduction to effective prevention and treatment methods for both adolescent and adult populations of NPS users.